The renewed interest in nuclear power is understandable. Rising electricity demand, energy security concerns and the growth of power-hungry data centres have all strengthened the case for dependable, low-carbon generation.

However, enthusiasm for a technology does not remove the commercial, regulatory and delivery risks surrounding it.

A recent Financial Times article reported that short sellers made an estimated $2.1 billion by betting against three US-listed small modular reactor (SMR) companies: NuScale Power, Nano Nuclear and Oklo. Collectively, the businesses had lost more than $30 billion from their peak market valuations.

The figures demonstrate two important lessons for those considering investment in emerging nuclear technologies.

The technology may be necessary, but the timetable still matters

Nuclear power will almost certainly be an important part of the future energy mix. However, political enthusiasm and an effervescent industry narrative have helped create unrealistic expectations about how quickly some SMR technologies can be deployed commercially.

The recent fall in market valuations is not necessarily evidence that the long-term case for nuclear power has disappeared. It is a reminder that investment returns and technological deployment do not always arrive on the timetable promised by market enthusiasm.

Investment in nuclear power may produce handsome returns over the longer term, but investors should not expect them this week.

Regulatory approval is only one stage of a much longer journey

Many SMR technologies remain unproven at commercial scale and must secure regulatory approval before progressing towards deployment.

Historically, moving from concept design to initial licensing can take five years or more. Development approval, financing, site preparation and construction can add another seven years or longer. Even where the underlying technology is credible, investors must account for the considerable capital requirements and the length of time before a project begins generating revenue.

The UK’s programme provides a useful example. Rolls-Royce SMR was selected as the Government’s preferred technology partner in June 2025 and entered into contract with Great British Energy – Nuclear in April 2026. However, its design remains within the Office for Nuclear Regulation’s Generic Design Assessment, while the Government expects the first projects to connect to the grid in the mid-2030s.

Follow commitment, not excitement

The less fashionable opportunities may not offer the most spectacular projected returns, but it makes sense to pay close attention to technologies receiving sustained government support.

Public investment does not remove risk or guarantee commercial success. It can, however, provide a useful indication of which technologies have passed meaningful scrutiny and have a credible route through regulation, financing and deployment. The UK Government has committed £2.6 billion to its SMR programme, demonstrating the scale of public backing required to move nuclear technology from design to delivery.

The lesson is not that investors should abandon SMRs. It is that technological potential, regulatory progress and commercial readiness must not be treated as the same thing.

In a sector characterised by long development periods, high capital costs and considerable political attention, disciplined due diligence matters. Investors should look beyond the excitement surrounding a technology and assess whether it has credible government backing, a realistic regulatory pathway, secure financing and a deliverable route to market.